Nanomedicine News

RSS

Calando Pharmaceuticals Initiates Phase II Clinical Trial of Nanoparticle-Based IT-101

Calando Pharmaceuticals, Inc., a majority owned subsidiary of Arrowhead Research Corporation, announced today that it has initiated a Phase II clinical trial in the United States evaluating the safety and efficacy of its...

11 Sep 2008

Instrument to Provide Real-Time Images of Biological Processes

Instrument to Provide Real-Time Images of Biological Processes

Researchers at the University of New Mexico were recently awarded a three-year, $1.1 million grant from the W.M. Keck Foundation to support a research program within the Department of Physics. The program, titled "A Facility to Perform Bio-molecular Imaging; Real Time Phase Mapping of Biological Dynamics," is designed to provide real-time images of biological processes at nano and pico scale resolutions, a feat never achieved before.

11 Sep 2008

Computer Simulations Showing Evidence of Biological Evolution at Work on the Molecular Level

Computer Simulations Showing Evidence of Biological Evolution at Work on the Molecular Level

A Florida State University researcher who uses high-powered computers to map the workings of proteins has uncovered a mechanism that gives scientists a better understanding of how evolution occurs at the molecular level.

11 Sep 2008

Medical Nanotechnology Markets to Reach $1 Trillion by 2015

Research and Markets has announced the addition of the "Medical Nanotechnology Markets" report to their offering. Nanotechnology has reached critical mass. Nowhere is this more evident than in medicine. Ris...

From Research and Markets 10 Sep 2008

MagForce Nanotechnologies to Present at UBS Global Life Sciences Conference

MagForce Nanotechnologies AG will be presenting at this year’s UBS Global Life Sciences Conference in New York City. Dr. Uwe Maschek, CEO of MagForce Nanotechnologies, will provide an investor overview of the compa...

From MagForce Nanotechnologies AG 10 Sep 2008

New International Alliance to Establish Protocols for Toxicological Testing of Nanomaterials

A team of materials scientists and toxicologists announced the formation of a new international research alliance to establish protocols for reproducible toxicological testing of nanomaterials in both cultured cells and ...

9 Sep 2008

Former Engelhard Executive Lauds Nanostellar's Clean Technology Applications and Business Model

Nanostellar, Inc., a company developing and licensing materials for cleantech applications using rational design, today announced that Dr. Edward T. Wolynic has been appointed to the company's board of directors. ...

9 Sep 2008

EUREKA Program Funds Innovative Research on Neural Nanomachines

ASU can now shout the classic exclamation of discovery - "Eureka!" - twice. Fueled by a new initiative at the National Institutes of Health called the EUREKA program, two ASU teams have received million-doll...

9 Sep 2008

Promising Pre-Clinical Data Treating Liver Cancer Using siRNA

Tekmira Pharmaceuticals Corporation announced today that one of its collaborators, the National Cancer Institute (NCI), has presented promising pre-clinical data treating liver cancer using small interfering RNA (siRNA) ...

9 Sep 2008

Exciting Advances in the Ability to Work at the Atomic Level to be Unveiled at nanotxUSA'08

Among the more dramatic tools to be demonstrated during International Nanotechnology Week at the Hyatt Regency Dallas convention hotel October 2-3 is by InsituTec Inc, a Nano-Tool company commercializing an innovative pl...

9 Sep 2008

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.